3 results on '"Badawy, Sherif M."'
Search Results
2. Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia.
- Author
-
Lund, Troy C., Ahn, Kwang Woo, Tecca, Heather R., Hilgers, Megan V., Abdel-Azim, Hisham, Abraham, Allistair, Diaz, Miguel Angel, Badawy, Sherif M., Broglie, Larisa, Brown, Valerie, Dvorak, Christopher C., Gonzalez-Vicent, Marta, Hashem, Hasan, Hayashi, Robert J., Jacobsohn, David A., Kent, Michael W., Li, Chi-kong, Margossian, Steven P., Martin, Paul L., and Mehta, Parinda
- Subjects
- *
CELL transplantation , *ACUTE leukemia , *CORD blood transplantation , *MYELOSUPPRESSION , *ORGAN donors - Abstract
Highlights • Remission at second transplantation extends survival. • The same donor preferred for both transplantations. • Mismatched cord blood should be avoided for a second transplantation. ABSTRACT Children with acute leukemia who relapse after hematopoietic cell transplantation (HCT) have few therapeutic options. We studied 251 children and young adults with acute myelogenous or lymphoblastic leukemia who underwent a second HCT for relapse after their first HCT. The median age at second HCT was 11 years, and the median interval between first and second HCT was 17 months. Most of the patients (n = 187; 75%) were in remission, received a myeloablative conditioning regimen (n = 157; 63%), and underwent unrelated donor HCT (n = 230; 92%). The 2-year probability of leukemia-free survival (LFS) was 33% after transplantation in patients in remission, compared with 19% after transplantation in patients not in remission (P =.02). The corresponding 8-year probabilities were 24% and 10% (P =.003). A higher rate of relapse contributed to the difference in LFS. The 2-year probability of relapse after transplantation was 42% in patients in remission and 56% in those in relapse (P =.05). The corresponding 8-year probabilities were 49% and 64% (P =.04). These data extend the findings of others showing that patients with a low disease burden are more likely to benefit from a second transplantation. Late relapse led to a 10% decrement in LFS beyond the second year after second HCT. This differs from first HCT, in which most relapses occur within 2 years after HCT. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Norkin, Maxim, Shaw, Bronwen E., Brazauskas, Ruta, Tecca, Heather R., Leather, Helen L., Gea-Banacloche, Juan, T. Kamble, Rammurti, DeFilipp, Zachariah, Jacobsohn, David A., Ringden, Olle, Inamoto, Yoshihiro, A. Kasow, Kimberly, Buchbinder, David, Shaw, Peter, Hematti, Peiman, Schears, Raquel, Badawy, Sherif M., Lazarus, Hillard M., Bhatt, Neel, and Horn, Biljana
- Subjects
- *
STEM cell transplantation , *STEM cell donors , *ERYTHROCYTES , *IMMUNOSUPPRESSION , *MYELOID leukemia - Abstract
Highlights • Late fatal infection (LFI) contributed to one-third of the deaths in both adult and pediatric hematopoietic cell transplantation (HCT) recipients surviving to 2 years post-HCT. • In adults age ≥20 years, receipt of matched unrelated donor (MUD) or mismatched unrelated donor (MMUD) HCT and male sex were associated with an increased risk of LFI. • In pediatric subjects, age ≥10 years, receipt of MUD or MMUD HCT, and inherited abnormalities of erythrocyte function were associated with an increased risk of LFI. ABSTRACT We analyzed late fatal infections (LFIs) in allogeneic stem cell transplantation (HCT) recipients reported to the Center for International Blood and Marrow Transplant Research. We analyzed the incidence, infection types, and risk factors contributing to LFI in 10,336 adult and 5088 pediatric subjects surviving for ≥2 years after first HCT without relapse. Among 2245 adult and 377 pediatric patients who died, infections were a primary or contributory cause of death in 687 (31%) and 110 (29%), respectively. At 12 years post-HCT, the cumulative incidence of LFIs was 6.4% (95% confidence interval [CI], 5.8% to 7.0%) in adults, compared with 1.8% (95% CI, 1.4% to 2.3%) in pediatric subjects; P <.001). In adults, the 2 most significant risks for developing LFI were increasing age (20 to 39, 40 to 54, and ≥55 years versus 18 to 19 years) with hazard ratios (HRs) of 3.12 (95% CI, 1.33 to 7.32), 3.86 (95% CI, 1.66 to 8.95), and 5.49 (95% CI, 2.32 to 12.99) and a history of chronic graft-versus-host disease GVHD (cGVHD) with ongoing immunosuppression at 2 years post-HCT compared with no history of GVHD with (HR, 3.87; 95% CI, 2.59 to 5.78). In pediatric subjects, the 3 most significant risks for developing LFI were a history of cGVHD with ongoing immunosuppression (HR, 9.49; 95% CI, 4.39 to 20.51) or without ongoing immunosuppression (HR, 2.7; 95% CI, 1.05 to 7.43) at 2 years post-HCT compared with no history of GVHD, diagnosis of inherited abnormalities of erythrocyte function compared with diagnosis of acute myelogenous leukemia (HR, 2.30; 95% CI, 1.19 to 4.42), and age >10 years (HR, 1.92; 95% CI, 1.15 to 3.2). This study emphasizes the importance of continued vigilance for late infections after HCT and institution of support strategies aimed at decreasing the risk of cGVHD. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.